Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Announce Earnings of -$0.63 Per Share – Defense World

Brokerages expect Vigil Neuroscience, Inc. (NASDAQ:VIGL Get Rating) to announce earnings per share (EPS) of ($0.63) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vigil Neurosciences earnings. The lowest EPS estimate is ($0.74) and the highest is ($0.57). The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Vigil Neuroscience will report full-year earnings of ($2.81) per share for the current financial year, with EPS estimates ranging from ($3.30) to ($2.45). For the next year, analysts forecast that the firm will post earnings of ($3.65) per share, with EPS estimates ranging from ($4.05) to ($3.02). Zacks earnings per share averages are an average based on a survey of research analysts that follow Vigil Neuroscience.

Vigil Neuroscience (NASDAQ:VIGL Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts consensus estimates of ($0.55) by ($0.03).

A number of institutional investors have recently modified their holdings of the business. Artal Group S.A. bought a new stake in Vigil Neuroscience in the first quarter worth about $7,882,000. Rock Springs Capital Management LP bought a new stake in Vigil Neuroscience in the first quarter worth about $3,318,000. Deep Track Capital LP bought a new stake in Vigil Neuroscience in the first quarter worth about $2,736,000. Vanguard Group Inc. bought a new stake in Vigil Neuroscience in the first quarter worth about $2,708,000. Finally, BlackRock Inc. bought a new stake in Vigil Neuroscience in the first quarter worth about $2,135,000. Hedge funds and other institutional investors own 39.39% of the companys stock.

Shares of NASDAQ VIGL opened at $3.39 on Friday. Vigil Neuroscience has a fifty-two week low of $2.18 and a fifty-two week high of $18.27. The companys 50-day moving average is $4.66.

Vigil Neuroscience Company Profile (Get Rating)

Vigil Neuroscience, Inc, a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.